LAVA Therapeutics NV (LVTX) Stock Price & Overview

NASDAQ:LVTX • NL0015000AG6

Current stock price

1.74 USD
-0.07 (-3.87%)
Last:

The current stock price of LVTX is 1.74 USD. Today LVTX is down by -3.87%. In the past month the price increased by 8.07%. In the past year, price increased by 8.75%.

LVTX Key Statistics

52-Week Range0.8502 - 2
Current LVTX stock price positioned within its 52-week range.
1-Month Range1.58 - 1.825
Current LVTX stock price positioned within its 1-month range.
Market Cap
45.779M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.86
Dividend Yield
N/A

LVTX Stock Performance

Today
-3.87%
1 Week
+2.35%
1 Month
+8.07%
3 Months
+13.73%
Longer-term
6 Months +35.94%
1 Year +8.75%
2 Years +14.79%
3 Years -68.42%
5 Years N/A
10 Years N/A

LVTX Stock Chart

LAVA Therapeutics NV / LVTX Daily stock chart

LVTX Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to LVTX. When comparing the yearly performance of all stocks, LVTX is one of the better performing stocks in the market, outperforming 75.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LVTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LVTX. While LVTX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LVTX Earnings

Next Earnings DateMar 26, 2026
Last Earnings DateNov 6, 2025
PeriodQ3 / 2025
EPS Reported-$0.27
Revenue Reported
EPS Surprise -8.04%
Revenue Surprise %

LVTX Forecast & Estimates

7 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -19.69% is expected in the next year compared to the current price of 1.74.

For the next year, analysts expect an EPS growth of 7.87% and a revenue growth -100% for LVTX


Analysts
Analysts45.71
Price Target1.4 (-19.54%)
EPS Next Y7.87%
Revenue Next Year-100%

LVTX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

LVTX Financial Highlights

Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 16.5% compared to the year before.


Income Statements
Revenue(TTM)11.98M
Net Income(TTM)-49.19M
Industry RankSector Rank
PM (TTM) N/A
ROA -69.12%
ROE -190.76%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%41.3%
Sales Q2Q%N/A
EPS 1Y (TTM)16.5%
Revenue 1Y (TTM)77.01%

LVTX Ownership

Ownership
Inst Owners27.59%
Shares26.31M
Float22.00M
Ins Owners0.73%
Short Float %N/A
Short RatioN/A

LVTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.92388.432B
AMGN AMGEN INC16.05197.413B
GILD GILEAD SCIENCES INC16.43179.993B
VRTX VERTEX PHARMACEUTICALS INC24.04119.226B
REGN REGENERON PHARMACEUTICALS16.1978.843B
ALNY ALNYLAM PHARMACEUTICALS INC42.7441.564B
INSM INSMED INC N/A30.069B
BIIB BIOGEN INC11.426.644B
NTRA NATERA INC N/A26.624B
UTHR UNITED THERAPEUTICS CORP17.8923.498B
MRNA MODERNA INC N/A20.758B
EXAS EXACT SCIENCES CORP341.6619.77B
RVMD REVOLUTION MEDICINES INC N/A18.798B

About LVTX

Company Profile

LVTX logo image LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Company Info

IPO: 2021-03-25

LAVA Therapeutics NV

Yalelaan 60

Utrecht UTRECHT NL

Employees: 34

LVTX Company Website

LVTX Investor Relations

Phone: 31630003035

LAVA Therapeutics NV / LVTX FAQ

What does LVTX do?

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.


Can you provide the latest stock price for LAVA Therapeutics NV?

The current stock price of LVTX is 1.74 USD. The price decreased by -3.87% in the last trading session.


Does LAVA Therapeutics NV pay dividends?

LVTX does not pay a dividend.


How is the ChartMill rating for LAVA Therapeutics NV?

LVTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Where is LAVA Therapeutics NV (LVTX) stock traded?

LVTX stock is listed on the Nasdaq exchange.


Can you provide the sector and industry classification for LAVA Therapeutics NV?

LAVA Therapeutics NV (LVTX) operates in the Health Care sector and the Biotechnology industry.